Do Disease-Modifying Medications Improve Lipid Levels in Heart Disease?
An RCT finds triple therapy with a statin, SGLT2 inhibitor, and PCSK9 inhibitor lowers lipids more than monotherapy in ischemic heart disease. PICO summary and commentary.
Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
Is Dapagliflozin Safe in Hospitalised COVID-19 Patients With and Without Type 2 Diabetes?
A prespecified DARE-19 analysis found dapagliflozin was safe and well tolerated in hospitalised COVID-19 patients regardless of type 2 diabetes status, with no demonstrated efficacy benefit. PICO summary and expert commentary.
Does Dapagliflozin Improve Heart Outcomes After a Heart Attack?
A DAPA-MI subanalysis finds dapagliflozin reduces new-onset diabetes after heart attack regardless of glucose or BMI, with most symptom benefit in prediabetes. PICO summary and commentary.
Intensive Blood Pressure Control in Diabetes With Prior Stroke: An ACCORD-BP Post-Hoc Analysis
A post-hoc analysis of 307 ACCORD-BP participants with type 2 diabetes and prior stroke links intensive systolic blood pressure control to fewer cardiovascular events. PICO summary and expert commentary.
Does Semaglutide Improve Lipid Profiles in Type 2 Diabetes?
A 52-week trial finds semaglutide shifts lipoprotein subfractions toward a less atherogenic profile in type 2 diabetes, independent of weight or glucose change. PICO summary and commentary.
Can a New Fat and Glucose Index Predict Heart Risks in Type 2 Diabetes?
An ACCORD analysis finds a triglyceride-glucose-waist index independently predicts cardiovascular events and mortality in type 2 diabetes, beating TyG alone. PICO summary and commentary.